Pulmonx (LUNG) CEO sells 67,813 shares for RSU tax withholding

Rhea-AI Filing Summary

Pulmonx Corp President and CEO Glendon E. French III reported open-market sales of 67,813 shares of common stock. The sales occurred on March 2, 2026 at $1.43 per share in three transactions. Footnotes state the shares were sold to cover tax withholding obligations tied to vesting of restricted stock units granted in 2022 and 2023. After these sales, he directly held 1,409,511 shares, with an additional 742,998 shares held indirectly by a family trust.

Insights

Equity compensation and insider trading analyst

CEO sales are tax-withholding related and look like routine equity compensation activity.

The filing shows Glendon E. French III, President and CEO of Pulmonx Corp, executed open-market sales totaling 67,813 common shares at $1.43 per share on March 2, 2026. The transactions are coded as sales of non-derivative common stock.

Footnotes clarify these shares were sold to satisfy tax withholding obligations upon vesting of restricted stock units granted in 2022 and 2023. That indicates the disposition is tied to equity award vesting rather than a discretionary portfolio decision described in the document.

Following the reported sales, French’s direct holdings stood at 1,409,511 shares, and 742,998 shares are held indirectly through a family trust where he and his spouse serve as trustees and beneficiaries. Any further details on future vesting or additional transactions would appear in subsequent company filings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

French Glendon E. III

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		2,708	D	$1.43	1,474,616	D
Common Stock	03/02/2026		S(2)		6,737	D	$1.43	1,467,879	D
Common Stock	03/02/2026		S(3)		58,368	D	$1.43	1,409,511	D
Common Stock								742,998	I	By trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

3. Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025.

4. The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.

	/s/ David Aaron Lehman, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Pulmonx (LUNG) CEO Glendon E. French III report?

He reported selling 67,813 Pulmonx common shares in open-market transactions on March 2, 2026 at $1.43 per share. These non-derivative sales reduced his direct holdings but were linked in the footnotes to tax withholding obligations from restricted stock unit vesting.

At what price did the Pulmonx (LUNG) CEO sell his shares and on what date?

All reported sales occurred on March 2, 2026 at $1.43 per share. The Form 4 lists three separate open-market transactions in Pulmonx common stock, each at this price, totaling 67,813 shares sold by President and CEO Glendon E. French III.

Why did the Pulmonx (LUNG) CEO sell 67,813 shares of common stock?

Footnotes state the shares were sold to cover tax withholding obligations related to vesting of restricted stock units granted in 2022 and 2023. The filing characterizes the transactions as sales connected to equity award vesting, not as standalone sales with another described purpose.

How many Pulmonx (LUNG) shares does the CEO hold after the reported transactions?

After the March 2, 2026 sales, Glendon E. French III directly owned 1,409,511 Pulmonx common shares. The filing also reports 742,998 additional shares held indirectly through a family revocable trust, where he and his spouse are trustees and beneficiaries.

What does the Pulmonx (LUNG) filing say about the CEO’s indirect share ownership?

The filing notes 742,998 shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust. It states the reporting person and his spouse serve as trustees and beneficiaries of this trust, which is reported as indirect ownership on the Form 4.

Are the Pulmonx (LUNG) CEO’s reported stock sales part of a derivative or option exercise?

No, the reported sales involve non-derivative common stock, according to the transaction classification. However, footnotes link the sales to tax withholding obligations from the vesting of restricted stock units granted in 2022 and 2023 rather than to a new option or warrant exercise.